Work

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Year: 2012
Type: article
Institutions: Institut Català d'Oncologia, USP Institut Universitari Dexeus, Centre François Baclesse, Hospital General Universitario de Alicante Doctor Balmis, Vall d'Hebron Hospital Universitari, Hospital General Universitario Gregorio Marañón, Hospital de Sant Pau, Hospital Universitario 12 De Octubre, MD Anderson Cancer Center Madrid, Universidad Autónoma de Madrid, Hospital Universitario Ramón y Cajal, Policlinico Umberto I, Hospital Clínico Universitario de Valencia, Azienda Ospedaliera San Camillo-Forlanini, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Hospital Son Llatzer, Centre Oscar Lambret, Hospital Universitario La Paz, Instituto Nazionale Tumori Regina Elena, Hospital Clínic de Barcelona, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Hospital Universitario de La Princesa, Hospital Universitario Puerta de Hierro Majadahonda, Complejo Hospitalario de Jaén, Hospital Universitario Son Dureta, Hospital Universitario Doctor Peset, Hospital Universitario Virgen de las Nieves, Hospital Clínico Universitario Lozano Blesa, Centre Hospitalier du Mans, Hôpital Larrey, Centre Hospitalier Universitaire d'Angers, Hospital Universitario Insular de Gran Canaria, Hospital de Cruces, La Maddalena, Hospital Universitario Nuestra Señora de Candelaria, Centre Hospitalier de Mulhouse, Hospital Universitario de Valme, Centro di Riferimento Oncologico, Hospital Universitario Miguel Servet, Sapienza University of Rome, Clinica Rotger, Universidad de Alcalá, Pivotal (Spain), Hospital Universitario Virgen del Rocío
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2111662961
FWCI: 361
Cites: 23
Cited by: 5,483
Related to: 10